Interestingly, heteronemin suppresses p53 expression and activity in cholangiocarcinoma [44] and oral cancer cells [11], suggesting that heteronemin does not induce anti-proliferation via a p53-dependent pathway. Here, TP53 is linked to cholangiocarcinoma.